Theravance Inc (THRX.OQ)

THRX.OQ on NASDAQ Stock Exchange Global Select Market

28.93USD
11 Jul 2014
Price Change (% chg)

$-0.03 (-0.10%)
Prev Close
$28.96
Open
$28.92
Day's High
$29.30
Day's Low
$28.77
Volume
128,940
Avg. Vol
387,837
52-wk High
$34.52
52-wk Low
$20.23

THRX.OQ

Chart for THRX.OQ

About

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including... (more)

Overall

Beta: 1.67
Market Cap (Mil.): $3,258.50
Shares Outstanding (Mil.): 112.63
Dividend: 0.25
Yield (%): --

Financials

  THRX.OQ Industry Sector
P/E (TTM): -- 35.37 35.77
EPS (TTM): -1.84 -- --
ROI: -35.81 19.00 18.27
ROE: -113.34 19.78 19.16
Search Stocks

BRIEF-GSK and Theravance says gains approval in Japan for Anoro Ellipta

* Press_release:anoro ellipta(umeclidinium/vilant erol) gains approval in Japan for the treatment of COPD

04 Jul 2014

BRIEF-GSK, Theravance submit sNDA to U.S. FDA for Breo Ellipta

* GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma

30 Jun 2014

BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan

* GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan

22 Apr 2014

UPDATE 1-GSK receives European nod for COPD drugs Anoro, Incruse

LONDON, Feb 20 - Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday.

20 Feb 2014

GlaxoSmithKline's COPD drug Anoro receives European green light

LONDON - Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday.

20 Feb 2014

GlaxoSmithKline's COPD drug Anoro receives European green light

LONDON, Feb 20 - Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday.

20 Feb 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks